Short answer
Amylyx Pharmaceuticals, Inc. (AMLX) filed an 8-K current report with the SEC on September 8, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Dual-source manufacturing secured for avexitide commercial supply, contingent on regulatory approval.
Amylyx Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Dual-source manufacturing secured for avexitide commercial supply, contingent on regulatory approval
- Bachem agreement requires minimum annual purchases beginning 2028, creating future volume commitments
- Polypeptide term sheet includes a $30 million upfront capacity-reservation fee
- Polypeptide arrangement remains subject to negotiating and executing a definitive manufacturing agreement
- Five-year initial Bachem term with automatic three-year renewals, adding long-term supply-cost exposure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amylyx Pharmaceuticals, Inc. 8-K filings
Get the next AMLX 8-K as it lands
Follow AMLX for push alerts, or ask the research agent what this filing means.